

ANNUAL REPORT

NEURO5SCIENCE CANADA



ANNUAL REPORT 2005

NEUROSCIENCE CANADA

NeuroScience Canada (NSC) is a national non-profit organization that develops and supports collaborative, multidisciplinary, multi-institutional research across the neurosciences. Through partnering with the public, private and voluntary sectors, NeuroScience Canada connects the knowledge and resources available in this area to accelerate neuroscience research and funding, and maximize the output of Canada's world-class scientists and researchers.

TABLE OF CONTENTS

Message from the Chair and President	
– Celebrating a year of excellence and innovation	2
The Brain Repair Program™	
– Connecting neuroscience research across the country	4
Progress of first Brain Repair Program™ teams	
– Accelerating the pace of discovery	5
A portfolio of partnered research programs	
– Supporting world-class science	6
Board of Directors	8
Science Advisory Council	9
Board development	
– Building trust through good governance	10
Science Advisory Council news	
– Drawing on the expertise of scientists across Canada and around the world	11
Fundraising activities	12
Stewardship and donor cultivation	12
Public awareness and advocacy activities	13
Brain Awareness Week	13
New logo for NeuroScience Canada!	13
Thanks to donors, partners and campaign volunteers	14
Financial report	16

Learn more about **NeuroScience Canada** by visiting our website:
www.neurosciencecanada.ca.

Find out facts about our organization, the latest news, information about our programs, notes on how to apply for funds, and links to other sites of interest. Past annual reports can also be downloaded.



NeuroScience
CANADA

NeuroScience Canada
2155 Guy Street, Suite 900, Montreal, Quebec, Canada H3H 2R9
T (514) 989 2989 **F** (514) 989 1331
info@neurosciencecanada.ca
www.neurosciencecanada.ca

Partnership Registration Number: 86870 6326 RR0001
Foundation Registration Number: 89105 2094 RR0001

1 IN 3 CANADIANS WILL BE AFFECTED BY A DISEASE, DISORDER OR INJURY OF THE BRAIN, SPINAL CORD OR NERVOUS SYSTEM AT SOME POINT IN THEIR LIVES.

BRAIN DISORDERS ARE AMONG THE LEADING CAUSES OF DEATH AND THE LEADING CAUSE OF DISABILITY.

BRAIN DISORDERS ACCOUNT FOR 38% OF THE ECONOMIC BURDEN OF ILLNESS, BASED ON WORLD HEALTH ORGANIZATION DATA.

RESEARCH IS THE KEY TO UNRAVELING THE INTRICACIES OF THE BRAIN AND NERVOUS SYSTEM. IT IS THE ONLY HOPE FOR FINDING THERAPIES AND CURES.

MISSION STATEMENT

NEUROSCIENCE CANADA AIMS TO BE:

THE PRE-EMINENT PRIVATE SOURCE OF FUNDS IN CANADA TO SUPPORT NEUROSCIENCE RESEARCH CAPACITY BUILDING WITHIN MULTIDISCIPLINARY RESEARCH PROGRAMS;

A LEADER IN NEUROSCIENCE RESEARCH STRATEGIC PLANNING AND A MAJOR PARTNER WITH THE PUBLIC SECTOR AND VOLUNTARY HEALTH ORGANIZATIONS IN DEVELOPING AND SUPPORTING THE NEUROSCIENCE RESEARCH AGENDA; AND

AN IMPORTANT VOICE FOR INNOVATIVE NEUROSCIENCE RESEARCH AS A PUBLIC GOOD.

MESSAGE FROM THE CHAIR AND PRESIDENT

CELEBRATING A YEAR OF EXCELLENCE AND INNOVATION

The pursuit of excellence and drive for innovation: these are the characteristics that distinguish every successful organization. This past year, NeuroScience Canada saw the results of our hard work in all areas – our science program, fundraising campaign, public awareness activities, and general operations.

In 2003, NeuroScience Canada launched the Brain Repair Program™, with the goal of accelerating excellent and innovative research aimed at exploring the brain's ability to be repaired or to repair itself. Following our first competition, three multidisciplinary, multi-institutional teams of researchers were awarded grants of \$1.5 million over three years, commencing October 2004. The progress of these teams has been remarkable: within the first year of their grant, all three have had breakthrough discoveries published in major peer-reviewed science journals. This is a clear indication that our “virtual team” model, which enables our best researchers across the country to join their efforts and fast-track their work, is delivering concrete results. In January 2006, we were pleased to launch the second Brain Repair Program competition to fund the final two teams of our five-team objective. We look forward to announcing the results in the fall of 2006.

To support our Brain Repair Program and other research programs, we have been working steadily towards our \$11.5-million National Brain Repair Fund Campaign goal. To date (May 2006), we have raised \$10,204,095, and we expect to close our campaign later this year. This will be a major milestone for NeuroScience Canada, but we have set ourselves even more ambitious post-campaign targets, recognizing the ever-urgent need for research funding. Our fundraising activities have brought us into contact with some truly exceptional people, and in 2005, we received a \$1.5-million commitment from the WB Family Foundation (T. Robert Beamish family) in Ontario. It is a great honour to be associated with this distinguished family.

In addition to our fundraising activities, we continue to grow and expand our partnerships with other organizations that are supporting Canadian neuroscience research. We have been working closely with the Canadian Institutes of Health Research, and in particular, the Institute of Neurosciences, Mental Health and Addiction, and the Institute of Aging; the Ontario Neurotrauma Foundation; and the Barbara Turnbull Foundation for Spinal Cord Research. These relationships greatly enrich our work.

We have also begun collaborating with organizations as part of a national effort to give one strong voice to the grouping of brain, spinal cord and nervous system diseases, disorders and injuries linked to neuroscience. These organizations include: the Canadian Association for Neuroscience; the Canadian Congress of Neurological Sciences; and the Canadian Brain and Nerve Health Coalition. In 2006, we published *The Case for Canada's Increased Investment in Neuroscience Research*. This is the first time that an organization has provided key statistics on the burden of all brain disorders, and called upon governments and the general public to increase their support of Canada's world-class neuroscience research.



Dr. David Kaplan, Vice-Chair Science and Chair, Science Advisory Council;
the Honourable Michael H. Wilson, Chair;
Ms. Inez Jabalpurwala, President;
Mr. J. Anthony Boeckh, Vice-Chair Administration and Chair, Audit and Finance Committee.

To reinforce NeuroScience Canada's unique position as the umbrella organization for brain disorders, the advertising agency AMEN generously donated their services to create a new logo and sharper image. We are very excited about the design, which depicts the brain and incorporates the umbrella, in a stylized yet clear manner. We thank AMEN for their work and look forward to a positive partnership with them in the future, as we continue to build our brand.

Good governance is a priority for NeuroScience Canada, essential to transparency, monitoring, accountability—to building trust with our stakeholders. We were therefore delighted when our strength in this area was recognized and we received The Conference Board of Canada/Spencer Stuart 2006 National Awards in Governance award for the not-for-profit sector. These awards "single out bold and innovative solutions to governance challenges, and organizations that have broken new ground in the search for governance excellence".

Finally, in March 2006, the Honourable Michael H. Wilson, Chair of the NeuroScience Canada Partnership from 1999-2003, and Chair of the integrated Partnership and Foundation from 2003, was appointed the Canadian Ambassador to the United States. This is a tremendous opportunity for him and for Canada, and we wish him the very best in his new role. Mr. Wilson was actively involved in all aspects of our strategy and operations, led our fund-raising, recruited volunteers for the campaign and our Board, engaged and enrolled partners, and raised awareness about the need for increased funding for neuroscience research, as a matter of public good. Mr. Wilson's departure is a great loss for NeuroScience Canada, and he is deeply missed by everyone associated with this organization. However, we have invited him to continue his association with NeuroScience Canada, as our Honourary Chair.

As we look forward to the years ahead, excellence and innovation will remain the means to our end goal of advancing the field of neuroscience, and ultimately, discovering new treatments and cures for brain disorders.

With many thanks to all of our supporters,



Mr. Andrew J. MacDougall, President, Spencer Stuart Canada; **Ms. Anne Golden**, President and CEO, The Conference Board of Canada; **Mr. Allan R. Taylor**, Chair, Governance Committee, NeuroScience Canada; and **Mr. Phillip Crawley**, Publisher and CEO, *The Globe and Mail*.

A handwritten signature in black ink, appearing to read "Allan R. Taylor".

Allan R. Taylor
Interim Chair of the Board

A handwritten signature in black ink, appearing to read "Inez Jabalpurwala".

Inez Jabalpurwala
President

THE BRAIN REPAIR PROGRAM™

CONNECTING NEUROSCIENCE RESEARCH ACROSS THE COUNTRY

In 2003, NeuroScience Canada launched the \$8-million Brain Repair Program with the goal of fast-tracking excellent and innovative brain repair research. Brain repair is a new field of multidisciplinary, collaborative research aimed at exploring the brain's ability to be repaired or to repair itself. This field focuses on mechanisms common across brain, spinal cord and nervous system diseases, disorders and injuries, such as: cell loss, the abnormal functioning of nerve cells, and chemical and molecular imbalances. The Brain Repair Program is linking world-class researchers across Canada and providing them with the opportunity to utilize the investments in infrastructure and salaries that have already been made by governments and private donors.

Each team of researchers receives \$1.5 million over three years, plus up to an additional \$20,000 per year for networking activities. These are the largest grants in Canada for brain repair research. The Brain Repair Program is aligned with the Canadian Institutes of Health Research's (CIHR) Strategic Initiative in Regenerative Medicine. The CIHR is our major partner and provided a \$1.5-million grant for the first competition. Another major contributor to the first competition was an Anonymous Donor (now deceased) who provided a \$1.2-million challenge gift.

The review process for the first Brain Repair Program competition was rigorous and highly competitive and included an international peer review component featuring distinguished neuroscientists from around the world. Three teams have been funded through the Brain Repair Program, and their research covers the range of neurological and psychiatric disorders, as well as spinal cord injuries and chronic pain. The first three Brain Repair Program teams have just completed the first year of their grant and are already making significant advances in their research. All three had their results published in prestigious science journals.

On January 26th, 2006, NeuroScience Canada launched the second Brain Repair Program competition, through which we will select two additional teams for funding. This second competition was made possible thanks to a leadership gift of \$1.5 million from the WB Family Foundation (T. Robert Beamish family) in Ontario. The Ontario Neurotrauma Foundation was our provincial partner on the first competition and we are delighted that they will be partnering with us again on this second competition. We also have a commitment from the Canadian Institute of Health Research's Institute of Aging to partner on a team that is conducting research that is aligned with their areas of focus.

NeuroScience Canada received 16 Letters of Intent for the second Brain Repair Program competition and our Science Advisory Council selected five to advance to the Full Application stage. These full applications will be reviewed by our International Review Committee, and the two highest-ranking teams within the "excellent to outstanding" range along the Canadian Institutes of Health Research scale will be funded. The results will be announced in fall 2006.

PROGRESS OF FIRST BRAIN REPAIR PROGRAM™ TEAMS

ACCELERATING THE PACE OF DISCOVERY

NOVEL APPROACHES TO CENTRAL NERVOUS SYSTEM WHITE MATTER REPAIR

Goal – Using a stem-cell approach, the goal is to repair damaged, demyelinated nerve cells, which are implicated in a range of disorders including multiple sclerosis, spinal cord injuries and schizophrenia.

First year progress – The team has discovered a new protein in nerve cells called p63, whose levels determine whether nerve cells live or die. It is suspected that this protein is involved in nerve cell death associated with neurological and neurodegenerative conditions.

Publications

December 8th, 2005 *Neuron* – “P63 Is an Essential Proapoptotic Protein during Neural Development”

TRANSFORMING RESEARCH ON CHRONIC PAIN

Goal – The goal is to understand the mechanisms of chronic pain, which can lead to the development of a new generation of drugs aimed at selectively targeting and treating chronic pain and repairing damaged nervous function. Chronic or neuropathic pain is caused by nerve damage brought on by injury or illnesses such as cancer, HIV/AIDS or diabetes.

First year progress – The team has found strong evidence that chronic pain is not caused by a direct effect on nerves, but rather, by cells in the body called microglia that make substances that injure nerves. They have discovered a protein that causes spinal neurons to send abnormal signals to the pain-processing networks of the brain. This is a key step in elucidating the mechanisms of neuropathic pain and could lead to better diagnostics and new therapeutics in the future, and help the thousands of Canadians who suffer from chronic pain.

Publications

December 15th, 2005 *Nature* – “BDNF from Microglia Causes the Shift in Neuronal Anion Gradient Underlying Neuropathic Pain”

NOVEL THERAPEUTIC STRATEGIES TO REPAIR BRAIN ABNORMALITIES IN PSYCHIATRIC DISORDERS

Goal – The goal is to explore a novel method for treating psychiatric disorders, whereby drugs can target the specific brain cells and communication pathways in need of repair, and restore the balance of chemical messengers, without any negative side effects.

First year progress – The team has found a way to use an interference peptide to block the communication between brain cells that trigger drug cravings. When this chemical communication is disrupted, the brain is tricked into forgetting the euphoric effects of drug addiction. This finding could lead to the development of drugs that target specific brain cells for treatment of people with addictions and psychiatric illnesses.

Publications

February 16th, 2006 *Neuron* – “A Preformed Complex of Postsynaptic Proteins Is Involved in Excitatory Synapse Development”

November 25th, 2005 *Science* – “Nucleus Accumbens Long-Term Depression and the Expression of Behavioral Sensitization”



Team leader: **Dr. Freda Miller,**

University of Toronto


Members: Dr. David Kaplan, University of Toronto; Dr. Wolfram Tetzlaff, University of British Columbia; Dr. Samuel Weiss, University of Calgary.



Team leader: **Dr. Michael W. Salter,**

University of Toronto

Members: Dr. Karen D. Davis, University of Toronto; Dr. Yves De Koninck, Université Laval; Dr. Jeffrey Mogil, McGill University; Dr. Min Zhuo, University of Toronto.



Team leader: **Dr. Yu Tian Wang,**

University of British Columbia;

Members: Dr. Stephen S.G. Ferguson, University of Western Ontario;

Dr. Alaa El-Husseini, University of British Columbia; Dr. Ridha Joober, McGill University; Dr. Anthony G. Phillips, University of British Columbia.

A PORTFOLIO OF PARTNERED RESEARCH PROGRAMS

SUPPORTING WORLD-CLASS SCIENCE

ALBERTA INITIATIVE

The Alberta Initiative was developed with the purpose of retaining excellent young neuroscience researchers at three Alberta universities: University of Calgary, University of Alberta and University of Lethbridge. Gifts to the Alberta Initiative were combined with Alberta Heritage Foundation for Medical Research (AHFMR) funds, effectively multiplying support. The AHFMR also conducted the peer review to select the award recipients.

To date, we have allocated \$597,650 to fund eight fellowships and 22 studentships. These funds were matched by the AHFMR at a ratio of 7:3. An additional \$125,000 was allocated to support two researchers in Dr. Samuel Weiss' lab at the University of Calgary, as part of Dr. Freda Miller's Brain Repair Program™ project.

A further \$75,000 has been directed to support research that looks at mental illness and concurrent disorders as determinants of homelessness. Two leading researchers, Dr. James R. Dunn and Dr. Paula Goering, are conducting a project in Toronto and Calgary titled: *Feasibility Study for a Two-City Demonstration of Supportive Housing for Individuals with Severe Mental Illness*. Drs. Dunn and Goering are undertaking a pilot study in the cities of Toronto and Calgary, of the effects of supportive housing on people with severe and persistent mental illness (SPMI). Of particular interest is the effect of supportive housing on future housing stability, quality of life, functioning, symptoms, and health care utilization for people with SPMI.

BARBARA TURNBULL AWARD FOR SPINAL CORD RESEARCH

This award, in support of Canadian research on spinal cord injury, is funded by NeuroScience Canada, in partnership with the Barbara Turnbull Foundation for Spinal Cord Research and the Canadian Institutes of Health Research (CIHR) Institute of Neurosciences, Mental Health and Addiction (INMHA). The award recipient is selected from among the CIHR-funded investigators for that year, judged to be doing the most promising and exciting research in this area. NeuroScience Canada and the Barbara Turnbull Foundation for Spinal Cord Research each provide \$25,000 for a total of \$50,000. This amount is added to the \$300,000 operating grant that the CIHR is providing to the researcher over three years.

In 2005, the recipient of the Barbara Turnbull Award for Spinal Cord Research was Dr. Joseph Culotti, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, for his research project titled: *Axon Guidance and Cell Migration Mechanisms in C. elegans*. Dr. Culotti is studying how proteins function to guide cell growth movement in the roundworm *C. elegans*. This research will help lead to an understanding of regeneration and development in the human nervous system. Dr. Culotti was presented with the award at a ceremony at Mount Sinai Hospital on March 2nd, 2006. Present at the ceremony were representatives from CIHR, NeuroScience Canada, the Barbara Turnbull Foundation for Spinal Cord Research, Mount Sinai Hospital, and many of Dr. Culotti's colleagues.

FOR FURTHER DETAILS ABOUT THE ALBERTA INITIATIVE, INCLUDING THE LIST OF ALL STUDENTSHIPS AND FELLOWSHIPS, PLEASE GO TO THE "PROGRAMS" SECTION OF OUR WEBSITE, AND FOLLOW THE LINKS TO "PARTNERED PROGRAMS," AND "ALBERTA INITIATIVE".



Ms. Barbara Turnbull, President, The Barbara Turnbull Foundation for Spinal Cord Research; with **Dr. Joseph Culotti**, recipient of the 2005 Barbara Turnbull Award for Spinal Cord Research; and Bella.

COGNITIVE IMPAIRMENT AND AGING

NeuroScience Canada is a member of the Cognitive Impairment in Aging (CIA) Partnership. The CIA Partnership is a collaboration between government, non-government and industry groups led by the CIHR's Institute of Aging. Its mission is to improve knowledge in the area of cognitive impairment by coordinating increased research efforts that in turn will facilitate the development, application and evaluation of interventions, services and products for older people. As of June 1st, 2005, \$15.3 million has been committed by CIA partners towards a range of research programs, supporting individuals and teams doing research in this area.

DR. NORMA CALDER SCHIZOPHRENIA POST-DOCTORAL FELLOWSHIP

The Dr. Norma Calder Schizophrenia Post-Doctoral Fellowship is a partnership of NeuroScience Canada and the Dr. Norma Calder Schizophrenia Foundation in British Columbia (now known as the Mind Foundation of BC), to fund a post-doctoral fellow at the University of British Columbia conducting research on schizophrenia, within the CIHR's Health Partnership Program. The award recipient receives \$41,500 per year, for three years. NeuroScience Canada's contribution was \$10,375 per year, from 2003–2005.

In 2003, a peer-review panel selected Dr. Clare L. Beasley as the recipient of the fellowship, which began in September 2003. Dr. Beasley is a former resident of the United Kingdom and completed her PhD at the University of Sheffield. She was a research fellow at the Institute of Psychiatry in London. Dr. Beasley's research was titled: *Investigating the Possible Role of Proteins, Lipids and Metabolites in Schizophrenia*.

Dr. Beasley's project involved examining the levels of myelin (the fatty sheath covering axons which is essential for the fast conduction of nerve impulses) in the grey matter in subjects with schizophrenia and mood disorders. Results indicated that the concentration of cholesterol, a lipid found at high levels in myelin, was decreased in bipolar disorder and major depressive disorders, but not in schizophrenia. The results of this investigation were published in the October 2005 issue of the journal *Bipolar Disorders*.


SASKATCHEWAN SCHIZOPHRENIA RESEARCH PROGRAM

The Saskatchewan Schizophrenia Research Program is a \$1-million, five-year program that could lead to earlier diagnosis and improved treatment for people with this serious brain disorder. Funding partners include AstraZeneca Canada, the CIHR's Institute of Neurosciences, Mental Health and Addiction, the Royal University Hospital Foundation, the Schizophrenia Research Foundation Saskatchewan, the Saskatoon chapter of the Schizophrenia Society of Saskatchewan and the College of Medicine. NeuroScience Canada provided an additional \$30,000 to this program.

Dr. Xin-Min Li and his research team have developed research projects which demonstrate that the combined administration of antidepressants and atypical antipsychotics produce synergistic effects in protecting animals from stress-induced changes in behavior and hippocampal neuroplasticity, which is compromised in patients with depression or schizophrenia. Several publications in leading scientific journals have already resulted from this research.



Dr. Clare L. Beasley,
Recipient of the Dr. Norma Calder Schizophrenia
Post-Doctoral Fellowship.



Dr. Xin-Min-Li,
Team Leader of the Saskatchewan
Schizophrenia Research Program.

BOARD OF DIRECTORS

INTERIM CHAIR

Allan R. Taylor, O.C., LL.D (Hon)

Chair, Governance Committee
Retired Chairman and CEO
Royal Bank of Canada
(Toronto)

IMMEDIATE PAST CHAIR

Michael H. Wilson, PC, O.C., DSL, LL.D (Hon.)

Canadian Ambassador to the United States
(Washington)

VICE-CHAIR ADMINISTRATION

J. Anthony Boeckh, PhD

Chair, Audit and Finance Committee
Member, Governance Committee
Member, Public Policy and Communications Committee
President
Boeckh Capital Company Limited
(Montreal)

VICE-CHAIR SCIENCE

David Kaplan, PhD

Chair, Science Advisory Council
Member, Governance Committee
Member, Public Policy and Communications Committee
Head, Cancer Research Program
The Hospital for Sick Children;
Canada Research Chair
in Cancer and Neuroscience
(Toronto)

DIRECTORS

Albert J. Aguayo, O.C., MD, FRSC

Special Advisor,
Public Policy and Communications Committee
President
International Brain Research Organization
Montreal General Hospital Research Institute
(Montreal)

Vincent Castellucci, PhD

Associate Vice-Dean for Research
Faculty of Medicine
Université de Montréal
(Montreal)

Marcel Côté

Chair, Public Policy and Communications Committee
Founding Partner and President
SECOR
(Montreal)

Rupert Duchesne

President and CEO
Aeroplan
(Montreal)

Inez Jabalpurwala

President and Secretary-Treasurer
NeuroScience Canada Partnership
and NeuroScience Canada Foundation
(Montreal)

Charles Kaplan

Member, Audit and Finance Committee
Vice President and R&D Site General Manager
AstraZeneca R&D
(Montreal)

Mark Krembil

President
The Krembil Foundation
(Toronto)

Brandt C. Louie, FCA, LL.D (Hon.)

President and CEO
H.Y. Louie Company Limited;
Chairman and CEO
London Drugs Limited
(Vancouver)

Anthony G. Phillips, PhD, FRSC

Member, Public Policy and Communications Committee
Director, UBC Institute of Mental Health
Professor, Department of Psychiatry
University of British Columbia
(Vancouver)

Richard B. Stein, PhD

Professor Emeritus of Physiology and Neuroscience
Centre for Neuroscience
University of Alberta
(Edmonton)

John M. Stewart, LL.B

Partner, Toronto Office
Blake, Cassels & Graydon LLP
(Toronto)

Franco J. Vaccarino, PhD

Professor and Chair
Department of Psychology
University of Toronto
(Toronto)

HONOURARY MEMBERS

Warren C. Bull

Executive Director
Former Neuroscience Network
(Ottawa)

Rick Hansen, C.C., O.B.C.

President and CEO
Rick Hansen Man in Motion Foundation
(Vancouver)

David L. Johnston, C.C., LL.B, LL.D

President
University of Waterloo
(Waterloo)

Ronald N. Mannix

Chairman
Coril Holdings
(Calgary)

Heather Munroe-Blum, O.C., PhD, FRSC

Principal and Vice-Chancellor
McGill University
(Montreal)

Jean-Marie Poitras, O.C., O.Q.

Former member of the Senate
(Quebec City)

J. Robert S. Prichard, O.C., O.Ont, LL.M, PhD (Hon)

President and CEO
Torstar Corporation;
President Emeritus
University of Toronto
(Toronto)

Barbara Turnbull

President
The Barbara Turnbull Foundation
for Spinal Cord Research
(Toronto)



Members of NeuroScience Canada's Board of Directors

(from left to right) Back row: Dr. Albert J. Aguayo, Mr. John M. Stewart, Dr. Franco J. Vaccarino, Dr. Anthony G. Phillips, Mr. Mark Krembil, Mr. Marcel Côté.
Front row: Dr. David Kaplan, the Honourable Michael H. Wilson, Ms. Inez Jabalpurwala, Mr. J. Anthony Boeckh.

SCIENCE ADVISORY COUNCIL

CHAIR

David Kaplan, PhD

Head, Cancer Research Program
The Hospital for Sick Children;
Canada Research Chair
in Cancer and Neuroscience

Inez Jabalpurwala, Ex-officio member

President
NeuroScience Canada

MEMBERS

Albert J. Aguayo, O.C., MD, FRSC

President
International Brain Research Organization
Montreal General Hospital Research Institute

M. Catherine Bushnell, PhD

Director, Centre for Research on Pain
McGill University

Vincent Castellucci, PhD

Associate Vice-Dean for Research
Faculty of Medicine
Université de Montréal

Dale Corbett, MSc, PhD

Professor of Neurosciences
Faculty of Medicine
Memorial University of Newfoundland;
Canada Research Chair in Stroke
and Neuroplasticity (Tier I)

James L. Henry, PhD

Professor and Chair
in Central Pain
McMaster University;
Scientific Director
Michael G. DeGroote Institute for Pain
Research and Care

Larry M. Jordan, MSc, PhD

Professor of Physiology and Co-Director
Spinal Cord Research Centre,
Health Sciences Centre;
Director, Neuroscience Research Program
University of Manitoba

Stanley P. Kutcher, MD, FRCPC

Director, International Psychiatry
Department of Psychiatry;
Associate Dean, International Medical
Development and Research
Faculty of Medicine
Dalhousie University

Andres M. Lozano,

MD, PhD, FRCSC, BMedSci

Head and Senior Scientist
Division of Applied
and Interventional Research
Toronto Western Research Institute

Anthony G. Phillips, PhD, FRSC

Director, UBC Institute of Mental Health
Professor, Department of Psychiatry
University of British Columbia

Richard Riopelle, MD

Chair, Department of Neurology
and Neurosurgery
McGill University

Serge Rossignol, MD, PhD

Director
Centre for Research in Neurological Sciences
Université de Montréal

Guy Rouleau, MD, PhD, FRCP (C)

Professor, Department of Medicine
Université de Montréal;
Director, Centre for the Study of Brain Diseases
Centre hospitalier de l'Université de Montréal;
Adjunct Professor,
Department of Genetics
McGill University;
Canada Research Chair in Genetics
of the Nervous System (Tier 1)

James T. Rutka,

MD, PhD, FRCSC, FACS, FAAP

Professor and Chair
Division of Neurosurgery
University of Toronto;
Co-director and Principal Investigator
The Sonia and Arthur Labatt
Brain Tumour Research Centre
The Hospital for Sick Children

Peter St. George-Hyslop,

MD, FRCPC(C), FRS

Director, Centre for Research
in Neurodegenerative Diseases
University of Toronto;
Director, Toronto Western Research Institute

Richard B. Stein, PhD

Professor Emeritus of
Physiology and Neuroscience
Centre for Neuroscience
University of Alberta

Donald T. Stuss, PhD, FRSC, O.Ont.

Professor of Psychology and Medicine
(Neurology, Rehabilitation Science)
University of Toronto;
Director, The Rotman Research Institute;
The Reva James Leeds Chair in
Neuroscience and Research Leadership
Baycrest Centre for Geriatric Care

Franco J. Vaccarino, PhD

Professor and Chair
Department of Psychology
University of Toronto

Samuel Weiss, PhD

Director, Hotchkiss Brain Institute;
Professor, Departments of Cell Biology
and Anatomy & Pharmacology
and Therapeutics
University of Calgary

INTERNATIONAL SCIENCE ADVISORY COUNCIL

Larry Benowitz, PhD

Director, Laboratories for Neuroscience
Research in Neurosurgery
Children's Hospital (*Boston*);
Associate Professor of Neurosurgery
(Neuroscience)
Harvard Medical School
(*Boston, Massachusetts*)

Gary E. Landreth, PhD

Professor of Neurosciences and Neurology
Alzheimer Research Laboratory
Case Western Reserve University
School of Medicine
(*Cleveland, Ohio*)

Lorne M. Mendell, PhD

Distinguished Professor and Chair
Department of Neurobiology and Behaviour
SUNY at Stony Brook
(*Stony Brook, New York*)

Alain Privat, MD, PhD

Director, Spinal Cord Team
Institut des Neurosciences
(*Montpellier, France*)

Peter R. Rapp, PhD

Associate Professor
Kastor Neurobiology of Aging Laboratories
Mount Sinai School of Medicine
(*New York, New York*)

Scott R. Whittemore, PhD

Professor and Vice-Chairman for Research
Department of Neurological Surgery;
Henry D. Garretson Endowed Chair
in Spinal Cord Injury Research;
Scientific Director,
Kentucky Spinal Cord
Injury Research Center
University of Louisville School of Medicine
(*Louisville, Kentucky*)

BOARD DEVELOPMENT

BUILDING TRUST THROUGH GOOD GOVERNANCE

In 2005, the Honourable Michael H. Wilson continued as Chair of NeuroScience Canada (until March 2006). Mr. Allan R. Taylor stayed on as Chair of the Governance Committee. Mr. J. Anthony Boeckh retained his position as Vice-Chair Administration and Chair of the Audit and Finance Committee, while Dr. David Kaplan continued as Vice-Chair Science and Chair of the Science Advisory Council. Mr. Marcel Côté was Chair of the Public Policy and Communications Committee.

The Governance Committee provides counsel on all governance matters, ensuring that we operate with the highest standards of ethics and are transparent and fully accountable to our stakeholders. The Audit and Finance Committee reviews budgets and financial statements on a regular basis. The Public Policy and Communications Committee develops and presents, for Board approval, strategies and action plans to advance NeuroScience Canada's efforts to raise awareness of the incidence of neurological and psychiatric diseases, disorders and injuries. All three committees work closely with the President and report to the Board of Directors.

In 2005, NeuroScience Canada's Board of Directors appointed two new Directors: Mr. Rupert Dushesne, President and CEO, Aeroplan; and Mr. Mark Krembil, President, Krembil Foundation. Both were highly recommended by their peers and their participation has greatly enriched Board discussions.

In addition, the Board of Directors appointed four new Honourary Board Members: Dr. Heather Munroe-Blum, Principal and Vice-Chancellor, McGill University; Mr. Warren C. Bull, Executive Director, former NeuroScience Network; Mr. Rick Hansen, President and CEO, Rick Hansen Man in Motion Foundation; and Mr. J. Robert S. Prichard, President and CEO, Torstar Corporation. Dr. Munroe-Blum, Mr. Bull, and Mr. Prichard are all past Directors and enthusiastically agreed to remain involved with NeuroScience Canada.

GOOD GOVERNANCE HAS HAD AN IMPACT ON ALL AREAS OF OPERATIONS:

1. it has ensured that NeuroScience Canada has the right leadership to achieve its mission;
2. it has ensured that there is regular monitoring of activities and that the President is well supported;
3. it has enabled the organization to build trust with key stakeholders (internal and external).

On February 8th, 2006, NeuroScience Canada won the Conference Board of Canada/Spencer Stuart 2006 National Awards in Governance award for the not-for-profit sector. The National Awards in Governance single out bold and innovative solutions to governance challenges, and organizations that have broken new ground in the search for governance excellence. According to Mr. Andrew MacDougall, President, Spencer Stuart Canada and co-chair of the awards program: "These awards are all about how Boards and governing bodies can be creative and innovative in working 'smarter,' not just 'harder,' to secure the long-term success and sustainability of their enterprises".

Mr. Allan R. Taylor, Chair of NeuroScience Canada's Governance Committee, accepted the award on behalf of Neuroscience Canada at a black tie dinner in Toronto on February 8th, 2006. The next day, Mr. Taylor discussed NeuroScience Canada's governance innovations at the Conference Board's 2006 Corporate Governance Conference: *Striking the Right Balance*.

SCIENCE ADVISORY COUNCIL NEWS

DRAWING ON THE EXPERTISE OF SCIENTISTS ACROSS CANADA AND AROUND THE WORLD

In 2005, NeuroScience Canada's Science Advisory Council (SAC) provided valuable leadership and advice on our science programs. The SAC convened on May 3rd, 2005 to review and assess the first Brain Repair Program™ competition and results, in order to make any refinements before launching the second Brain Repair Program competition. In January 2006, this competition was announced and members undertook the important task of reviewing the Letters of Intent that were received. The review process included a teleconference to discuss the process and any issues which arose during the review.

In the past year, the following new members were welcomed to the SAC: Dr. Dale Corbett, Professor of Neurosciences for the Faculty of Medicine at Memorial University of Newfoundland and Canada Research Chair in Stroke and Neuroplasticity (Tier I); and Dr. Larry M. Jordan, Professor of Physiology, Co-Director of the Spinal Cord Research Centre; and Director of the Neuroscience Research Program at the University of Manitoba; and Dr. Guy Rouleau, Professor in the Department of Medicine at Université de Montréal; Director of the Centre for the Study of Brain Diseases at the Centre hospitalier de l'Université de Montréal; Adjunct Professor in the Department of Genetics at McGill University; and Canada Research Chair in Genetics of the Nervous System (Tier I).

INTERNATIONAL SCIENCE ADVISORY COUNCIL

Following the close of the first competition, many of the international reviewers asked how they could continue to be involved with NeuroScience Canada. As NeuroScience Canada wanted to develop and expand the relationships we had established with the science/research community outside Canada, in October 2004, we appointed these reviewers as members of our International Science Advisory Council (ISAC). The mandate of this council is: to provide advice to NeuroScience Canada's Board of Directors; review the progress of NeuroScience Canada-funded programs; provide suggestions of peers (from outside Canada) to be approached to review new applications in subsequent Brain Repair Program competitions; and serve as ambassadors of NeuroScience Canada outside of Canada.



Members of NeuroScience Canada's Science Advisory Council

(from left to right) Dr. Anthony G. Phillips, Dr. Albert J. Aguayo, Dr. Richard B. Stein, Dr. Richard Riopelle, Dr. M. Catherine Bushnell, Dr. James L. Henry, Ms. Inez Jabalpurwala, Dr. Franco J. Vaccarino, Dr. David Kaplan, Dr. Vincent Castellucci, Dr. Samuel Weiss, Dr. Donald T. Stuss.

FUNDRAISING ACTIVITIES

In 2001, NeuroScience Canada launched the \$10-million National Brain Repair Fund Campaign, with the goal of supporting excellent neuroscience research in Canada. This goal was subsequently revised to \$11.5 million. From January 1st, 2005 to May 1st, 2006, we raised a total of \$2,257,252, bringing our campaign total to \$10,204,095.

The highlight of our fundraising year was the confirmation of a \$1.5-million gift from the WB Family Foundation (T. Robert Beamish family) in Ontario. This leadership gift enabled NeuroScience Canada to launch the second Brain Repair Program™ competition in January 2006.

We are pleased to announce several other large gifts in 2005, including \$300,000 from Scotiabank Group; \$150,000 from Manulife Financial (their second gift for a total of \$300,000); \$210,000 from Magna International; and US\$45,000 from the BP Foundation. We are very grateful for the generosity of these valued supporters.

The fundraising success in 2005 was due to a stronger case for support, focused on our Brain Repair Program, and to the efforts of a team of committed campaign volunteers, led by the Honourable Michael H. Wilson. These volunteers, along with members of our Board, are assisting us with our requests for donations from individuals, corporations and foundations.

STEWARDSHIP AND DONOR CULTIVATION

In order to raise awareness about Canadian neuroscience research and NeuroScience Canada's efforts to support and accelerate this research, we have been hosting small gatherings across the country.

In 2005, NeuroScience Canada held such events in Vancouver (March 7th, 2005), hosted by Dr. Brandt C. Louie, President and CEO, H. Y. Louie Company Limited and a NeuroScience Canada Director; Toronto (January 17th, 2006), hosted by Mr. Thomas C. MacMillan, President and Chief Executive Officer, CIBC Mellon; and Montreal (February 6th, 2006), hosted by the Honourable Michael H. Wilson. These dinners brought together NeuroScience Canada's Directors, members of the Science Advisory Council, researchers, donors, volunteers and other stakeholders.

GUESTS AT NEUROSCIENCE CANADA'S MONTREAL EVENT ON FEBRUARY 6TH, 2006



Mr. John M. Stewart,
the Honourable W. David Angus and
the Honourable Michael H. Wilson.



Dr. Robert M. Levine, President and CEO,
the Henry and Berenice Kaufmann Foundation;
Dr. Michael Salter, Brain Repair Program
team leader; **Ms. Janis L. Levine,**
Co-President and CEO, the Henry
and Berenice Kaufmann Foundation.



Dr. Ridha Joobor, Co-Director, Schizophrenia
and Neurodevelopmental Disorders Research
Theme, Douglas Hospital Research Centre;
Dr. Ashok Malla, Director, Clinical Research
Division, Douglas Hospital Research Centre;
Dr. Jacques Hendlisz, Director General,
Douglas Hospital; **Dr. Anthony G. Phillips,**
NeuroScience Canada Director.

PUBLIC AWARENESS AND ADVOCACY ACTIVITIES

Over the past year, NeuroScience Canada has taken on a leadership role to raise awareness about the incidence and impact of diseases, disorders and injuries of the brain, spinal cord and nervous system; how common mechanisms link these conditions; how excellent Canadian neuroscience research can reduce this burden; and the corresponding need for governments and private donors to increase funding for neuroscience research.

On March 15th, 2006, NeuroScience Canada released a document titled: *The Case for Canada's Increased Investment in Neuroscience Research (Case)*. The *Case* contains consolidated data from a variety of sources, including Health Canada, the World Health Organization, and the Canadian Institutes of Health Research. NeuroScience Canada received input on the *Case* from the Public Policy and Communications Committee Advisory Council, as well as other neuroscience stakeholder groups, such as the Canadian Association for Neuroscience and the Canadian Brain and Nerve Health Coalition. The *Case* can be downloaded from NeuroScience Canada's website.

BRAIN AWARENESS WEEK

Brain Awareness Week (BAW), created by the Dana Alliance for Brain Initiatives, is an international partnership of government agencies, scientific organizations, universities, and volunteer groups. It includes more than 1,850 partner organizations in 62 countries.

In 2006, BAW took place the week of March 13–17. NeuroScience Canada asked all of the Canadian chapters of the Society for Neuroscience to provide details of any BAW activities that they were planning. The events were compiled into a media advisory, and this was disseminated nationally.

On March 15th, 2006, NeuroScience Canada collaborated with the Montreal Chapter of the Society for Neuroscience and the Montreal Science Centre, on a BAW public event. The event consisted of hosting presentations of the IMAX movie “Wired to Win – Surviving the Tour de France”.

NEW LOGO FOR NEUROSCIENCE CANADA!

As part of NeuroScience Canada's branding, we have adopted a new logo. The new logo is a simple shape, made up of two lines that depict the brain. Also visible in the logo is the idea of the “umbrella,” which corresponds with NeuroScience Canada's positioning as the umbrella organization for brain disorders. This new logo will be used on all of our communications materials and is part of NeuroScience Canada's branding strategy. We are very grateful to the Montreal-based design agency AMEN, which created the new logo for us as a generous pro bono. AMEN also produced a new brochure and this annual report for NeuroScience Canada, at substantially reduced rates, and will be working with us on other projects. To find out more about AMEN, you can visit their website at <http://www.amencreation.com>.



Mr. Carl Grenier, President, AMEN; and
Mr. David Kessous, Senior Designer, AMEN.

THANKS TO DONORS, PARTNERS AND CAMPAIGN VOLUNTEERS

NeuroScience Canada extends a special thank you to an Anonymous Donor (now deceased), whose \$1.5-million challenge gift provided the impetus to launch the National Brain Repair Fund Campaign, and the Alberta Initiative,

and to

The WB Family Foundation (T. Robert Beamish family), whose \$1.5-million leadership gift enabled NeuroScience Canada to launch the second Brain Repair Program™ competition.

Their generosity has inspired many others to support our work and we are ever grateful to them.

We also wish to express our thanks to our federal partner:

NeuroScience Canada is proud to honour our lead corporate donors and our other major corporate donors who share our vision of advancing Canadian neuroscience research:

\$1.5 MILLION



The Canadian Institutes of Health Research and its Institute of Neurosciences, Mental Health and Addiction and Institute of Aging

\$750,000 + (CUMULATIVE GIVING)



\$500,000

A heartfelt thanks, as well, goes to our provincial partner:



For what matters.

\$250,000



\$300,000



We are also proud to honour the individuals and foundations who are major supporters of our work:



\$250,000

\$250,000 - \$500,000



Max Bell Foundation

The John Dobson Foundation

The J.W. McConnell Family Foundation

\$100,000 - \$249,999

\$100,000 - \$249,999

Boeckh Family

David and Dorothy Lam Foundation

The Tong and Geraldine Louie Family Foundation

Ronald N. Mannix

Allan R. and Shirley Taylor

The Barbara Turnbull Foundation
for Spinal Cord Research

Michael H. Wilson

BMO Financial Group

Great-West Life, London Life and Canada Life

Magna International Inc.

Power Corporation of Canada

NEUROSCIENCE CANADA THANKS ALL OTHER INDIVIDUALS, FOUNDATIONS AND CORPORATIONS WHO HAVE GENEROUSLY CONTRIBUTED TO OUR NATIONAL BRAIN REPAIR FUND CAMPAIGN AND OUR ALBERTA INITIATIVE.

Achber, Vernon
The Adair Family Foundation
Aeroplan
Aguayo, Albert J.
Alpaca Ventures
AstraZeneca Canada Inc.
ATCO Ltd.
BP Foundation Inc.
Baillie, James C.
Barrington Petroleum Ltd.
Beddis, Ian D.
Bell Canada Enterprises
Bhayana Management
Blundell, William
Boardwalk Charitable Trust Fund
The Graham Boeckh Foundation
Bois, Pierre
Borden Ladner Gervais
The Brookfield Foundation
The R.P. Bratty Charitable Foundation
The Marjorie and Gerald Bronfman Foundation
Bull, Warren C.
The Calgary Foundation/David and Leslie Bissett Fund
Canadian Council of Christians and Jews
Canadian Insurance Accountants Association
Canadian Pensions and Benefits Institute, Ontario
Regional Council
Castellucci, Vincent
Colangelo, Johanne
Colangelo, Lina
Corbertex Corporation
Côté, Marcel
Crouch, Pauline
Crown Life Insurance Company
Cumming, Tom and Mary
Dion, Durrell & Associates Inc.
Mitzi & Mel Dobrin Family Foundation
Dorrington, Keith J.**
Fraser, Anne
Gagnier, Jean-Marcel
Govain, Royal A.
Guest, Gowan
Harris, Cathy
Harvie, Donald**
Haskayne, Richard F.
Hotchkiss, Harley N.
Hyndman, Lou D.
Inasco Limited, Imperial Tobacco and Pharmaprix/
Shoppers Drug Mart
Jabalpurwala, Inez
Jabalpurwala, Kaizer E.
Jackman Foundation
The Norman and Margaret Jewison Charitable
Foundation
Johnston, David
Kaplan, Charles
The Henry and Berenice Kaufmann Foundation

Laliberté, June
Laliberté, Natasha
Lawson, Brian D. and Joannah
Lebrun, Manon
William F. Lede Family Foundation
The Alvin and Mona Libin Foundation
Lind, Philip B.
Lippman Leebosh April
London Drugs Foundation
Louie, Brandt C.
Love, G. Donald**
MacDonald, Patricia
Mackenzie Financial Services Inc.
Mackie, James
Manitoba Medical Students Association
McCaig, M. Ann
McLachlin, Ian Van C.
Melcor Developments Ltd.
Merck Frosst Canada Ltd.
Mississauga South Federal Progressive
Conservative Association
Muller, Linda
Munroe-Blum, Heather
Newall, J.E. (Ted)
Pannitti, Louise
Peters, Robert G.
Phillips, Anthony G.
RBC Investments
The Real Canadian Superstore
Robb, Christopher J.
Rothney, Bruce M.
Rygiel, Edward K.
SGI
Saskatchewan Wheat Pool
SaskTel TelCare
Savard, Guy
The Seagram Company Ltd.
St. Joseph's Healthcare Foundation
Stein, Richard B.
Stewart, John M.
Stripp, Bitten
TD Bank Financial Group
Tavender, Carolyn and David
Tétreault, Marielle
Theanon Charitable Foundation
The Toronto Star
Toronto Dominion Centre/The Cadillac Fairview
Corporation Limited
Torstar Corporation
TransCanada Pipelines Ltd.
Trimac Corporation
The William and Nancy Turner Foundation,
UBS Bank (Canada)
van Roon, Kenneth and Petrula
Viner, Paula
George Weston Limited
Wynne-Edwards, Hugh

**deceased

We make every effort to ensure the accuracy

of this list. If we have made any errors, please accept our apologies.

We also extend a special thank you to our donors who made gifts to honour the memory of the following individuals:

Rocky Colangelo
Vincenzo Maiorano

A special fund was established in the name of Dr. Hubert van Tol, who passed away suddenly on April 20th, 2006. Dr. van Tol was an internationally recognized and respected neuroscientist, who received numerous awards and greatly advanced the whole field of molecular neurobiology. This is a terrible loss, and we extend our heartfelt condolences to his family members, friends and colleagues.

NeuroScience Canada wishes to thank the following funders and partners for providing in-kind and other invaluable support:

Allon Therapeutics Inc. (formerly Neuro Discovery Inc.)

AMEN

Blake, Cassels & Graydon LLP

Canada Economic Development for Quebec Regions

Canadian Association for Neuroscience and the Society for Neuroscience

Thomas C. MacMillan

The McGill University Health Centre Foundation

VOLUNTEER LEADERSHIP FOR THE NATIONAL BRAIN REPAIR FUND CAMPAIGN

The commitment and energy of our campaign leaders and volunteers across Canada are a constant source of inspiration.

National Brain Repair Fund Campaign

The Honourable Michael H. Wilson,
National Chair (Toronto) (until March 13th, 2006)
W. David Angus (Montreal)
J. Anthony Boeckh (Montreal)
Marcel Côté (Montreal)
Lili de Grandpré (Montreal)
Rupert Duchesne (Montreal)
Alan S. Dunnett (Winnipeg)
George F. Gaffney (West Vancouver)
J. Douglas Grant (Toronto)
Stanley H. Hartt (Toronto)
Paul J. Hill (Regina)
Brian D. Lawson (Toronto)
Bruce M. Rothney (Toronto)
Robert K. Siddall (Winnipeg)
John M. Stewart (Toronto)

Alberta Initiative Volunteer Steering Group

Anne Fraser, Chair (Calgary)
Mary Cumming (Calgary)
William D. Hawley (Calgary)
Lou D. Hyndman (Edmonton)
Barbara J. Sparrow (Calgary)
Carolyn Tavender (Calgary)

2005 PARTNERSHIP AND FOUNDATION FINANCIAL REPORT AT A GLANCE

NEUROSCIENCE CANADA COMBINED FINANCIAL STATEMENTS

At December 31

	2005	2004
	\$	\$

ASSETS

Current Assets

Cash and cash equivalents	634 194	127 823
Temporary investments	2 363 906	3 354 351
Sundry receivables	42 154	18 550
Deposits	10 770	57 822
	<u>3 051 024</u>	<u>3 558 546</u>

Computer equipment	476	—
Investments		
in private companies	751	751
	<u>3 052 251</u>	<u>3 559 297</u>

LIABILITIES

Current Liabilities

Accounts payable		
and accrued liabilities	11 816	10 724
Current portion		
of program commitments	1 878 579	1 862 885
	<u>1 890 395</u>	<u>1 873 609</u>

Program commitments		
Long term - with funds allocated	747 403	1 169 743
	<u>2 637 798</u>	<u>3 043 352</u>

NET ASSETS

Unrestricted net assets	414 453	515 945
	<u>3 052 251</u>	<u>3 559 297</u>

At December 31

	2005	2004
	\$	\$

REVENUES

Restricted contributions	1 450 619	1 728 650
Canadian Institutes		
of Health Research	—	750 000
General contributions	22 459	10 000
	<u>1 473 078</u>	<u>2 488 650</u>
Less: deferred amount	406 646	(1 612 238)
	<u>1 879 724</u>	<u>876 412</u>

Government grants	—	13 353
Interest and other income	64 505	40 018
	<u>1 944 229</u>	<u>929 783</u>

EXPENDITURES

Grants and awards	1 656 190	524 640
Operating expenses	389 531	347 210
	<u>2 045 721</u>	<u>871 850</u>

Excess of revenues over expenditures for the year

	<u>(101 492)</u>	<u>57 933</u>
--	--------------------	---------------

The financial statements of NCP - NeuroScience Canada Partnership and NCF - NeuroScience Canada Foundation are audited by KPMG LLP and are available upon request.



Ethical Fundraising and Financial Accountability Code
NeuroScience Canada has adopted the Canadian Centre for Philanthropy's Ethical Fund Raising and Financial Accountability Code as its policy.